Real-time, 3-D microscopic tissue imaging could be a revolution for medical fields such as cancer diagnosis, minimally invasive surgery and ophthalmology. University of Illinois researchers have developed a technique to computationally correct for aberrations in optical tomography, bringing the future of medical imaging into focus.
The computational technique could provide faster, less expensive and higher resolution tissue imaging to a broader population of users. The group describes its technique this week in the online early edition of the Proceedings of the National Academy of Sciences.
"Computational techniques allow you to go beyond what the optical system can do alone, to ultimately get the best quality images and three-dimensional datasets," said Steven Adie, a postdoctoral researcher at the Beckman Institute for Advanced Science and Technology at the U. of I. "This would be very useful for real-time imaging applications such as image-guided surgery."
Aberrations, such as astigmatism or distortion, plague high-resolution imaging. They make objects that should look like fine points appear to be blobs or streaks. The higher the resolution, the worse the problem becomes. It's especially tricky in tissue imaging, when precision is vital to a correct diagnosis. . .View Full Article
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >
Computing the Best High-Resolution 3-D Tissue Images
Source: ScienceDaily (4/25/12)
"Real-time, 3-D microscopic tissue imaging could be a revolution for medical fields such as cancer diagnosis, minimally invasive surgery and ophthalmology."
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"Preeclampsia is a very exciting indication, and PSTI has the potential to completely change how we treat this insidious disease." (6/4/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert More >